Data obtained in our study demonstrated that miR‐144‐3p could be incorporated into EVs derived from hBMSCs and transferred into cervical cancer cells, where miR‐144‐3p exerted anti‐tumour properties through the target inhibition of CEP55 by suppressing malignant cellular biological behaviours in vitro, and inhibiting the tumorigenicity of cervical cancer cells in vivo. Here, CEP55 is linked to cervical cancer.